Ophtec Secures CE Marking for Aspheric Presbyopia-Correcting IOL

May 12, 2017: By Jon Swedien

OphtecOphtec has received CE marking for its Precizon Presbyopic, a new aspheric presbyopia-correcting IOL, the Netherlands company announced May 6.

The lens will be commercially launched in October 2017 during the annual conference of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

The product will initially be available in the European Union and a few selected markets, Ophtec said.

The Precizon Presbyopic IOL features a patent-pending continuous transitional focus (CTF) optical design.

The CTF design’s transitional zones offer a smooth, continuous transition from near to infinity vision, enabling surgeons to treat a wider range of presbyopic patients with confidence, Ophtec said.

The IOL appears to be able to forgive larger degrees of lens tilt and decentration, and this tolerance reduces photic phenomena, helping patients to adapt more naturally to their new vision, Ophtec said.

The lens is also designed to be less dependent on pupil size under all lighting conditions, Ophtec said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022